Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912. https://doi.org/10.1016/S0140-6736(14)61393-3.

Article  CAS  PubMed  Google Scholar 

Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. https://doi.org/10.1038/nrdp.2017.13.

Article  PubMed  Google Scholar 

Visanji NP, et al. The discovery of α‑synuclein in Lewy pathology of Parkinson’s disease: the inspiration of a revolution. Mov Disord Clin Pract. 2021;8(8):1189–93. https://doi.org/10.1002/mdc3.13312.

Article  PubMed  PubMed Central  Google Scholar 

Roodveldt C, et al. The immune system in Parkinson’s disease: what we know so far. Brain. 2024;147(10):3306–24. https://doi.org/10.1093/brain/awad256.

Article  PubMed  PubMed Central  Google Scholar 

Zamanian MY, Golmohammadi M, Amin RS, et al. Therapeutic targeting of Krüppel-like factor 4 and its pharmacological potential in Parkinson’s disease: a comprehensive review. Mol Neurobiol. 2024;61(6):3596–606. https://doi.org/10.1007/s12035-023-03800-2.

Article  CAS  PubMed  Google Scholar 

Zamanian MY, Giménez-Llort L, Nikbakhtzadeh M, et al. The therapeutic activities of metformin: focus on the Nrf2 signaling pathway and oxidative stress amelioration. Curr Mol Pharmacol. 2023;16(3):331–45. https://doi.org/10.2174/1874467215666230420125625.

Article  CAS  PubMed  Google Scholar 

Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72(21 Suppl 4):S1–136. https://doi.org/10.1212/WNL.0b013e3181a1d44c.

Article  PubMed  Google Scholar 

Singh A, Kabra A, Singh L. Role of Formononetin (Isoflavone) in Parkinson’s disease. Lett Appl Nanobiosci. 2025;14:72.

Google Scholar 

Nabavi SF, Braidy N, Gortzi O, et al. Fisetin: a promising flavonoid with diverse neuroprotective potentials. Neurochem Int. 2015;89:111–20. https://doi.org/10.1016/j.neuint.2015.06.005.

Article  CAS  Google Scholar 

Khan H, Sureda A, Nabavi SM, et al. Therapeutic potential of flavonoids in neurodegenerative diseases. Food Chem Toxicol. 2018;120:735–42. https://doi.org/10.1016/j.fct.2018.07.010.

Article  CAS  Google Scholar 

Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species and cancer: role of antioxidant enzymes. CNS Neurol Disord Drug Targets. 2014;13(8):1290–6. https://doi.org/10.2174/1871527313666141017105747.

Article  Google Scholar 

Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Neuron. 2017;94(6):1170–86. https://doi.org/10.1016/j.neuron.2017.05.042.

Article  Google Scholar 

Yamashita KY, Bhoopatiraju S, Silverglate BD, Grossberg GT. Biomarkers in Parkinson’s disease: a state of the art review. Biomarkers Neuropsychiatry. 2023;9:100074. https://doi.org/10.1016/j.bionps.2023.100074.

Article  Google Scholar 

McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation. 2006;3:6. https://doi.org/10.1186/1742-2094-3-6.

Article  CAS  Google Scholar 

Ghosh A, Roy A, Liu X, et al. Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease. J Neurochem. 2007;103(6):2354–66. https://doi.org/10.1111/j.1471-4159.2007.04916.x.

Article  CAS  Google Scholar 

Zhang Y, Liu X, Bai X, et al. Oxidative stress and neurodegeneration. Brain Res. 2013;1512:29–37. https://doi.org/10.1016/j.brainres.2013.03.035.

Article  CAS  Google Scholar 

Politis M, Wu K, Loane C, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients. Brain. 2010;133(3):585–96. https://doi.org/10.1093/brain/awp303.

Article  Google Scholar 

Mattson MP. Pathways towards and away from Alzheimer’s disease. Nat Rev Neurosci. 2008;9(10):757–68. https://doi.org/10.1038/nrn2421.

Article  CAS  Google Scholar 

Patel MY, Shah JV, Patel SB, et al. Neuroprotective effect of fisetin against MPTP-induced neurotoxicity in PC12 cells. Neurochem Res. 2012;37(10):2050–60. https://doi.org/10.1007/s11064-012-0808-0.

Article  Google Scholar 

Kumar A, Dogra S, Prakash A. Neuroprotective effects of fisetin against rotenone-induced neurotoxicity in rats. Neurotox Res. 2020;38(3):596–608. https://doi.org/10.1007/s12640-020-00191-5.

Article  Google Scholar 

Chang K‑H, Chen C‑M. The role of oxidative stress in Parkinson’s disease. Antioxidants. 2020;9(7):597. https://doi.org/10.3390/antiox9070597.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alikatte K, Akondi RB, Yerragunta Y, et al. Fisetin ameliorates rotenone-induced behavioral and biochemical impairments in rats. Neurochem Int. 2020;135:104688. https://doi.org/10.1016/j.neuint.2020.104688.

Article  CAS  Google Scholar 

Liu Y, Zhang Y, Li Y, et al. Fisetin protects against oxidative stress-induced neurotoxicity in SH-SY5Y cells. Cell Mol Neurobiol. 2022;42(1):1–15. https://doi.org/10.1007/s10571-021-01098-3.

Article  Google Scholar 

Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2011;7(6):311–22. https://doi.org/10.1038/nrneurol.2011.60.

Article  CAS  Google Scholar 

Chen X, Zhang M, Liu L, et al. Fisetin promotes dopaminergic neuron survival via BDNF signaling in a Parkinson’s disease model. Brain Res Bull. 2020;155:1–9. https://doi.org/10.1016/j.brainresbull.2020.04.003.

Article  CAS  Google Scholar 

Cao Y, Zhang Y, Wang N, et al. Fisetin modulates Parkinson’s disease-related gene expression and improves motor function in mice. Neuropharmacology. 2022;207:108963. https://doi.org/10.1016/j.neuropharm.2022.108963.

Article  CAS  Google Scholar 

Park JH, Lee S, Kim HJ. Acute oral and dermal toxicity evaluation of fisetin in rodents. Regul Toxicol Pharmacol. 2022;131:105169. https://doi.org/10.1016/j.yrtph.2022.105169.

Article  CAS  Google Scholar 

Khan A, Ullah H, Kim MO. Neuroprotective and toxicological evaluation of fisetin: dose-dependent effects in murine models. Front Pharmacol. 2021;12:674256. https://doi.org/10.3389/fphar.2021.674256.

Article  Google Scholar 

Zhao L, Wang D, Chen X. Subacute toxicity and biochemical evaluation of fisetin in rat models. Food Chem Toxicol. 2023;179:113961. https://doi.org/10.1016/j.fct.2023.113961.

Article  Google Scholar 

Li Y, Zhao H, Zhang Q. Subchronic oral toxicity assessment of fisetin in Sprague–Dawley rats. Toxicol Rep. 2021;8:1398–406. https://doi.org/10.1016/j.toxrep.2021.07.016.

Article  CAS  Google Scholar 

Singh A, Gupta N, Mehta R. Neuroprotective mechanisms and safety considerations of fisetin in Parkinson’s disease: an updated review. J Neurochem. 2024;170(4):721–38. https://doi.org/10.1111/jnc.15741.

Article  CAS  Google Scholar 

You Y, Cho JH, Lee KY. Evaluation of safety and tolerability of fisetin supplementation in healthy volunteers: a randomized pilot study. Nutrients. 2022;14(23):5098. https://doi.org/10.3390/nu14235098.

Article  Google Scholar 

Farr JN, Xu M, Weivoda MM, et al. Fisetin supplementation reduces senescence-associated secretory phenotype markers in healthy adults: a pilot cohort study. Aging Cell. 2023;23(1):e13942. https://doi.org/10.1111/acel.13942.

Article  CAS  Google Scholar 

Kumar S, Singh R, Sharma P. Pharmacokinetic interactions of dietary flavonoids with cytochrome P450 enzymes: Implications for drug safety and efficacy. Phytomedicine. 2021;85:153560. https://doi.org/10.1016/j.phymed.2021.153560.

Article  CAS  Google Scholar 

Singh SS, Singh S, Singh R. NF-κB-mediated neuroinflammation in Parkinson’s disease and potential therapeutic effect of polyphenols. Neurotox Res. 2020;37(3):491–507.